De-escalation strategy

Phase 3Small molecule

De-escalation strategy is one of 49 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionRecruiting

Acute Myocardial InfarctionPhase 3

Recruiting

Competition

Competitive Landscape

75 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

8 2

Plavix

Sanofi

Approved

6 3

Repatha

Amgen

Approved

3 4

Eliquis

Bristol-Myers Squibb

Approved

1 5

Zebeta

Teva

Approved

1 6

Radicava

Shionogi

Approved

1 7

Onglyza

AstraZeneca

Approved

—8

Januvia

ZZydus Therapeutics Inc.

Approved

3 9

Alka-Seltzer

AAbbott

Approved

2 10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

Study completion

NCT04755387

Clinical

Trials by Indication[1]

Unspecified1 trial

Ticagrelor De-escalation Strategy in AMI Patients

Recruiting·—·Phase 4·NCT04755387·2,312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for De-escalation strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — De-escalation strategy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for De-escalation strategy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dong-A University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDong-A University

De-escalation strategy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News